Ipsen (IPSEY) News Today → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free IPSEY Stock Alerts $30.16 -0.38 (-1.24%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartDividendHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartDividendHeadlinesShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineIpsen S.A. reports Q1 results; reaffirms full-year guidancemsn.com - April 24 at 8:52 AMIpsen Q1 Total-sales Up 13.3% At CER; Confirms 2024 Financial Guidancemarkets.businessinsider.com - April 24 at 1:54 AMIpsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidancefinance.yahoo.com - April 24 at 1:54 AMIpsen (OTCMKTS:IPSEY) Stock Passes Above Two Hundred Day Moving Average of $29.07americanbankingnews.com - April 23 at 3:20 AMIpsen Pharma: Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseasesfinanznachrichten.de - April 23 at 12:20 AMIpsen, Skyhawk Therapeutics To Develop RNA-Modulating Molecules For Rare Neurological Disordersmarkets.businessinsider.com - April 22 at 9:17 AMIpsen publishes its 2023 Universal Registration Documentfinance.yahoo.com - April 17 at 1:01 PMIpsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investorsseekingalpha.com - April 5 at 7:09 PMMarengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsenfinance.yahoo.com - April 2 at 7:51 AMIpsen S.A. publishes its 2023 Consolidated Financial Statementsglobenewswire.com - February 15 at 4:00 AMIpsen's Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDAfinancialpost.com - February 14 at 6:23 PMIpsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDAfinance.yahoo.com - February 13 at 5:20 PMIpsen gets FDA approval for pancreatic cancer drug regimenmsn.com - February 13 at 5:20 PMIpsen Shares Fall After Forecast of Lower Marginmarketwatch.com - February 8 at 9:32 AMBuilding on solid FY 2023 results, Ipsen anticipates four launches in 2024markets.businessinsider.com - February 8 at 9:32 AMIpsen FY23 Profit Flat, Sales Rise; Sees Growth In FY24, Backs Mid-term Viewmarkets.businessinsider.com - February 8 at 9:32 AMIpsen S.A. Non-GAAP EPS of €9.15, revenue of €3.13B; initiates FY24 outlookmsn.com - February 8 at 9:32 AMIpsen - Monthly information relative to the total number of voting rights and shares composing the share capitalfinance.yahoo.com - February 6 at 12:49 PMBiotech Stocks Facing FDA Decision In February 2024markets.businessinsider.com - January 31 at 8:18 AMIpsen Pharma: Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024finanznachrichten.de - January 22 at 7:48 PMLatest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024finance.yahoo.com - January 22 at 7:48 PMIpsen : FDA Grants Priority Review To Elafibranor NDA For Rare Cholestatic Liver Disease Treatmentmarkets.businessinsider.com - December 7 at 9:34 AMCapital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlookfinance.yahoo.com - December 7 at 9:34 AMIpsen Says Health Canada Approved Bylvay To Treat Pruritus Due To PFICmarkets.businessinsider.com - November 13 at 10:10 AMIpsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)finance.yahoo.com - November 13 at 10:10 AMIpsen 9-month Sales Upnasdaq.com - October 26 at 8:40 AMIpsen updates on E.U. Marketing Authorisation Application for odevixibat in Alagille syndromemarkets.businessinsider.com - October 23 at 4:16 AMIpsen Pharma: Ipsen updates on QM-1114 regulatory processfinanznachrichten.de - October 3 at 1:45 PMIpsen updates on QM-1114 regulatory processfinance.yahoo.com - October 3 at 1:45 PMLaura Ipsenfortune.com - September 28 at 10:11 AMIpsen celebrates 75 years of its location in Cherry Valleymsn.com - September 17 at 10:32 PMIpsen announces change in R&D leadership: Howard Mayer to retire, succeeded by Christelle Huguetfinance.yahoo.com - September 1 at 5:03 AMExelixis lead product hits main goal in Phase 3 prostate cancer trialmsn.com - August 21 at 10:08 AMUS FDA approves French drugmaker Ipsen's rare bone disorder drugmsn.com - August 17 at 5:07 PMUS Approves Ipsen’s Therapy for Rare Bone Diseasebloomberg.com - August 16 at 5:59 PMUS FDA Approves Ipsen's Rare Bone Disorder Drugusnews.com - August 16 at 5:59 PMUS FDA approves Ipsen’s SohonosTM (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressivafinance.yahoo.com - August 16 at 5:59 PMIpsen Pharma: Ipsen delivers solid H1 2023 results and upgrades its full-year guidancefinanznachrichten.de - July 28 at 1:39 PMIpsen Shares Rise After It Upgrades 2023 Outlookmarketwatch.com - July 27 at 7:22 AMIpsen delivers solid H1 2023 results and upgrades its full-year guidancefinance.yahoo.com - July 27 at 2:22 AMIpsen announces a simplification of the concert of its principal shareholders representing 56.62% of the share capital and 72.36% of voting rights - effective from December 19, 2023finance.yahoo.com - July 24 at 9:56 AMIpsen's Bylvay for Alagille Syndrome Recommended for Approval by EU Agencymarketwatch.com - July 21 at 1:07 PMIpsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndromefinance.yahoo.com - July 21 at 1:07 PMIpsen Pharma: Ipsen announces European Commission decision on palovarotene for the treatment of FOPfinanznachrichten.de - July 19 at 6:09 PMIpsen announces European Commission decision on palovarotene for the treatment of FOPuk.finance.yahoo.com - July 19 at 1:09 PMGenfit's Miss Is CymaBay Therapeutics' Gain: Analyst Says Rival Data Leaves Room for Seladelpar To Emerge As Best-In-Classmarkets.businessinsider.com - June 30 at 3:13 PMIpsen, Genfit's Elafibranor Shows Promise In Primary Biliary Cholangitis Patientsmsn.com - June 30 at 3:13 PMIpsen Pharma: Ipsen announces positive outcome of FDA Advisory Committee on investigational palovarotene for fibrodysplasia ossificans progressivafinanznachrichten.de - June 29 at 1:00 AMFDA Panel Votes In Favor Of Ipsen's Palovarotene For Ultra-rare Bone Diseasemarkets.businessinsider.com - June 29 at 1:00 AMIpsen announces positive outcome of FDA Advisory Committee on investigational palovarotene for fibrodysplasia ossificans progressivafinance.yahoo.com - June 29 at 1:00 AM Get Ipsen News Delivered to You Automatically Sign up to receive the latest news and ratings for IPSEY and its competitors with MarketBeat's FREE daily newsletter. Email Address Global crypto currency reset (41 major banks signed up) (Ad)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. IPSEY Media Mentions By Week IPSEY Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IPSEY News Sentiment▼0.140.41▲Average Medical News Sentiment IPSEY News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IPSEY Articles This Week▼71▲IPSEY Articles Average Week Get Ipsen News Delivered to You Automatically Sign up to receive the latest news and ratings for IPSEY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: 1933 Industries News 4Front Ventures News AB Science News Acreage News Acreage News Aleafia Health News Almirall News Amazonas Florestal News American Green News Avant Brands News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:IPSEY) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ipsen S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
